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A Ab bs st tr ra ac ct t
We report three Dutch families with familial clustering of (pre)neoplastic cervical disease, review the literature
on familial risks of cervical intraepithelial neoplasia (CIN) and cervical cancer, and discuss possible practical
guidelines for women with a family history of cervical cancer. Daughters and sisters of women with cervical
cancer have been reported to have a relative risk of 1.5-2.3 to develop this type of cancer. From a practical
clinical point of view, we suggest that as in women with an increased non-genetic risk to develop cervical cancer
(e.g. because of immunosuppressive therapy) increased surveillance to detect this tumour should be considered
in women with an increased risk based on family history. Cessation of smoking should be advised. As the use
of condoms at least prevents HPV re-infection its use can be recommended as a way to lower the cervical cancer
risk. Future studies to determine the genetic contribution to the development of cervical cancer should include
the paternal family history of cancer and, because genetic predisposition might express itself as a higher risk to
develop precursors of cervical cancer, carcinoma in situ and CIN grade II-III.
Familial Cervical Cancer: Case Reports, Review and Clinical Implications
Margreet Zoodsma
1, Rolf H. Sijmons
2, Elisabeth G.E. de Vries
3, Ate G.J. van der Zee
1
Departments of 1Gynaecology, 2Clinical Genetics and 3Medical Oncology, Groningen University Hospital, The Netherlands
Key words: cervical cancer, familial, family history, risk, screening 
Corresponding author: Ate G.J. van der Zee, MD PhD, Department of Gynaecology, Groningen University Hospital,
Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, The Netherlands. Phone +31 50 3613152, fax +31 50 3611806, 
e-mail: A.G.J.van.der.zee@og.azg.nl
Submitted: 14 May 2004 
Accepted: 18 May 2004 
I In nt tr ro od du uc ct ti io on n
Infection with oncogenic types of human papilloma
virus (HPV) is regarded as the main causal factor of
cervical cancer [1]. There is evidence to suggest that
genetic factors affecting an individual’s susceptibility to
HPV infection may influence the risk to develop cervical
cancer [2]. However, the genes involved and mutations
or variants in those genes remain to be fully established
[3]. As in other cancers, genetic susceptibility might
manifest  as  familial  clustering  of  cervical  cancer.
Although cervical cancer is the third most common
cancer in women worldwide [4], reports on familial cases
of cervical cancer, on calculated tumour risks for relatives
and, even more so, on its clinical implications are
relatively rare. Due to the national screening programme
cervical  cancer  is  not  a common  disease  in  the
Netherlands [5, 6], and no reports have been published
on familial clustering of cervical cancer in Dutch patients. 
In this paper we report three Dutch families with
multiple  cases  of  cervical  cancer  and  cervical
intraepithelial neoplasia (CIN), we review the literature
on familial occurrence of cervical (pre)neoplastic
disease  and  discuss  present  and  possible  future
practical clinical implications. 
C Ca as se e   r re ep po or rt ts s
Recently members of three non-related families
(pedigrees shown in Figures 1, 2 and 3, respectively)H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 100
were referred to our clinic with questions regarding
the possible hereditary nature of cervical cancer in
their  families  and  possible  preventive  options.
Because family histories of cancer may be inaccurate
[7], we verified the cervical cancer cases whenever
possible. 
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Pedigrees of the three families with three or four women with CIN or cervical cancer. Diagnosis or cause of death and age of diagnosis or death are mentioned
in the figure. 
= individual referred for genetic counselling
black symbols = diagnosis confirmed by medical records ASC = adenosquamous carcinoma of the cervix
grey symbols = medical records unavailable CCC = clear cell carcinoma of the cervix
hatched symbols = non-cervical cancer reported by family CIS = cervical cancer in situ
numbers in the symbols = number of individuals CIN = cervical intraepithelial neoplasia
CC = cervical cancer DM = diabetes mellitus
SCC = squamous cervical cancer CVA = cerebro-vascular accident
ACC = adenocarcinoma of the cervix ? = unknown medical history
In family 1, the index-patient (IV-3) was diagnosed
with a clear cell carcinoma of the cervix, FIGO stage Ib1
at the age of 24. No diethylstilbestrol (DES)-use by the
mother was reported. The maternal great-grandmother
(I-1) was reported by the family to have been diagnosed
with cervical cancer before the age of 50. The maternal
grandmother  (II-5)  had  been  diagnosed  with
adenosquamous carcinoma of the cervix and had died
at the age of 46. The paternal aunt (III-6) had been
diagnosed with squamous carcinoma in situ (CIS) of the
cervix  at  the  age  of  35,  which  was  treated  with
a conization. The diagnoses in IV-3, II-5 and III-6 could
be confirmed by checking the medical records. The
medical records of I-1 were no longer available. No
cervical cancer occurred in the family of III-3. The question
on referral was what advice should be given to young girls
of 16 and 15 years of age (IV-4 and IV-5, respectively). 
In family 2, the proband (III-7) was referred because
three of her sisters (III-1, 5 and 9) had been diagnosed
with cervical cancer or CIN, all confirmed by medical
records. They were under the impression that their
mother (II-6) had been diagnosed with cervical cancer
as well. However, checking medical records revealed
that she had been diagnosed with hyperplasia of the
endometrium instead. 
In family 3, three cases of cervical cancer or CIS,
all squamous cell carcinoma, confirmed by medical
recorts occurred in two generations (II-1, III-3 and 8).
The medical history of two half-sisters (III-1 and 2) was
unknown. 
HPV status was unknown in families 1, 2 and 3 and
the patterns of non-cervical cancer types reported in
these families were not suggestive of any known
hereditary cancer syndrome. 
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Furgyik  case-control relatives of 180  relatives of 105 7.9% vs. 1.1% (p<0.01) % of mothers with CIS/CC –
et al. [20] CIS/CC patients male consorts 7.5% vs. 1.0 % (p<0.01)  % of sisters with CIS/CC
15.6% % of mothers and/or sisters with CIS/CC –
Brinton  case-control 418 SCC patients 801 healthy women OR = 3.1 (p <0.05) family history of CC in patients vs. controls
et al. [18] 23 ASC patients OR = 9.9 (p <0.05)
40 AC patients OR = 2.49 (N.S.)
Ahlbom  longitudinal  263 MZ twins – RR = 4.8 (95% CI 3.0-7.6) risk for twin sister to develop CIS  39-46%
et al. [13] cohort study 395 DZ twins – RR = 2.4 (95% CI 1.5-3.8) risk for twin sister to develop CIS
twin study MZ vs. DZ RR = 2.0 (95% CI 1.1-3.5) comparing MZ and DZ twins
Hemminki  longitudinal  relatives of 125,569  relatives of 3,901,140 FRR = 1.79 (95% CI 1.75-1.84) risk for daughters of patients vs. daughters 11-15% (CIS)
et al. [12] cohort study CIS patients healthy women of healthy women to develop CIS
relatives of 13,982  FRR = 2.30 (95% CI 1.66-2.93) risk for daughters of patients vs. daughters 22-34% (CC) 
CC patients of healthy women to develop CC
Magnusson  nested   relatives of 71,533 relatives of 194,810 FRR = 1.83 (95% CI 1.77-1.88) risk for biologic vs. adoptive mothers –
et al. [21] case-control CIN/CIS/CC patients healthy women vs. FRR = 1.10 (95% CI 0.76-1.54)
study  FRR = 1.93 (95% CI 1.85-2.01)  risk for biologic vs. adoptive sisters
in cohort study vs. FRR = 1.15 (95% CI 0.82-1.57) 
FRR = 1.45 (95% CI 1.31-1.60)  risk for half-sisters (same mother or same father)
Magnusson  longitudinal relatives of 65,685 relatives of 189,635 – – 27%
et al. [14] cohort study CIN/CIS/CC patients healthy women
Hemminki  longitudinal relatives of 191,081 relatives of 5,935,132 RR = 1.51-1.77 (95% CI 1.33-2.10) risk for relatives of patients  –
et al. [22] cohort study CIS patients healthy women vs. relatives of healthy women
relatives of 21,727  RR = 1.73-2.12 (95% CI 1.37-3.17)
CC patients
Fischer  longitudinal relatives of 893 – 6.9% % of relatives with CC –
et al. [19] cohort study CC patients
Legend to Table 1
OR = odds ratio MZ = monozygotic CC = cervical cancer
RR = relative risk = the risk of cases compared with the risk of controls DZ = dizygotic SCC = squamous cell carcinoma
FRR = familial relative risk = the risk to the relatives of cases divided by the risk to the relatives of controls CIN = cervical intra-epithelial neoplasia ASC = adenosquamous carcinoma
Heritability = the proportion of total variance due to genetic variance CIS = carcinoma in situ  AC = adenocarcinomaH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 103
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R Re ev vi ie ew w   a an nd d   d di is sc cu us ss si io on n
Familial  clustering  of  cervical  cancer  might  be
coincidental, the result of shared exogenic risk factors,
shared genetic risk factors or a combination of these
factors. HPV is an established exogenic risk factor for
cervical cancer and CIN [8]. Others might be smoking
and use of oral contraceptives [9-11]. All these risk factors
may well be shared within families because of possible
shared lifestyles. Presently there is neither indication that
cervical cancer which presents in familial clusters develops
at a significantly earlier age [12] than sporadic cervical
cancer (considered to be a hallmark of hereditary cancer)
nor that its clinical behaviour differs from that of sporadic
cervical cancer. The heritability of cervical cancer has
been estimated between 22% and 46% [12-14]. As
publications on cases of familial clustering of cervical
cancer are relatively rare, more data are needed to arrive
at more precise estimations [15-17]. Reported figures on
familial cervical cancer in situ (CIS) and cervical cancer
are summarized in Table 1. Apart from three studies (the
study by Brinton et al [18], who investigated the family
history  of  women  with  cervical  cancer  in  a North
American population, the study by Fischer et al [19] in
a German population and Furgyik et al [20] in a Swedish
population), all other available studies used the Swedish
national cancer registers. Not surprisingly the results of
the Swedish studies are similar, although different methods
to investigate familial risks were used and results were
expressed in different types of risk units [12-14, 21, 22].
In these studies, a (familial) relative risk of about 1.5-2.3
for CIS and/or cervical cancer for first degree relatives of
affected women was reported, although some histological
subtypes might be associated with a higher risk. Only one
study included patients with severe dysplasia (CIN III) of
the cervix [21]. Because CIN III and II are considered to
be the precursors of cervical cancer [23, 24], a genetic
predisposition to cervical cancer might manifest itself as
not only cervical cancer and CIS, but also as CIN II and
III. Familial clustering of CIN II and III as well as CIS and
cervical cancer might therefore be expected to occur, as
shown in our family 2. Therefore, it would be logical to
include CIN II and III in the analysis of familial cervical
cancer risk, although CIN will not be readily observed in
populations without cervical cancer screening. 
So  far,  familial  cervical  cancer  risk  has  been
investigated  in  mother-daughter  and  sister-sister
relationships only, but the pedigree of family 1 might
suggest a paternally inherited genetic susceptibility for
(pre)neoplastic cervical disease. Future studies should
include the history of (cervical) cancer in the paternal
branch of the family, as ignoring the possibility of paternally
transmitted genetic susceptibility will underestimate the
genetic contribution to cervical cancer risk. 
The familial risks reported so far are in the same
order of magnitude as the familial relative risks (FRRs)
found  in  cancers  with  an  identified  hereditary
component such as breast, ovarian and colon cancer
[12]. In contrast to these tumour types, there is no
evidence yet for the existence of a highly penetrant
cervical cancer predisposition gene. 
To identify candidate genes associated with genetic
susceptibility to cervical cancer, genes currently under
investigation are the HLA genes and other genes that
are involved in cell-mediated immunity like IL-10, Tp53
and genes involved in the detoxification of carcinogens
found in tobacco smoke [2, 3, 25-30]. The products
of most of these genes are known to interact with the
exogenic agents mentioned earlier. No definitive
conclusion about genetic predisposition in familial
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General  3 years after onset of vaginal intercourse,  Annually; 70 years of age
population but do not start screening later than  change interval to every 2 to 3 years 
at 21 years of age in women older than 29 years  
of age who have had 3 consecutive 
negative cytology results 
Women who are  Start as in general population Screen twice in the first year  Continue screening as long
immunocompromised
1 after diagnosis
2; annually thereafter as patients are in reasonably 
good health
Women with a history  Start as in general population Annually Continue screening as long 
of in utero exposure as patients are in reasonably
to DES good health
1 including HIV+
2 diagnosis of condition associated with compromised immune system or start of immunocompromising therapy, respectivelyH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(2) 104
clusters of cervical cancer, including those that we have
reported, will be possible before genes responsible for
such predisposition have been convincingly identified. 
What medical advice should we give to women with
a family history of cervical cancer and/or its precursor
lesions? For practical purposes, and based on current
literature, close female relatives of the affected women
in the families we have reported and similar ones can
be presumed to have a moderately increased risk to
develop cervical cancer. This raises the issue of possible
primary and secondary preventive options. In these
women, adherence to screening programmes and
reducing exposure to known exogenic risk factors might
therefore be especially important. As HPV is the main
causal factor for developing cervical cancer and this
virus is spread mainly through sexual contact, use of
condoms might be advisable, since the use of condoms
at least prevents HPV re-infection and thus can be
a way to lower cervical cancer risk [31]. Another
well-studied risk factor for CIN and cervical cancer is
smoking [32-34]. Smoking has been suggested to be
a confounding effect caused by the association of
smoking with a lifestyle with an increased risk of HPV
infection [35], but in other studies, adjusted for HPV,
smoking appeared to be an independent risk factor
[34]. Szarewski et al [36] reported that smoking
cessation facilitated regression of CIN lesions. Thus,
smoking cessation should be advised, particularly in
women at an increased risk for cervical cancer. 
Recently new guidelines for the early detection of
cervical neoplasia and cancer were published by the
American  Cancer  Society  (ACS)  [37].  These
recommendations  include  more  frequent  cervical
screening for women who have been reported to be at
a higher risk for cervical cancer, because they are either
immunocompromised  (by  organ  transplantation,
chemotherapy or chronic corticosteroid treatment) or
have a history of in utero exposure to diethylstilbestrol
(DES). Interestingly, no recommendations were included
for women with a positive family history of CIN or
cervical cancer although the relative risk for cervical
cancer due to DES exposure [38] is comparable to that
for cervical cancer due to familial clustering. Similar
relative  risks  have  lead  to  recommendations  for
increased surveillance in women with a family history of
cancer of the breast, ovaries or colon. Taken together,
it appears to be consistent to consider a more intensive
screening policy for women with a family history of
cervical cancer as well. In our opinion, this screening
could follow the ACS guidelines for other groups of
women with an increased cervical cancer risk, in
particular those listed for women with a history of in utero
exposure to DES (Table 2), until more data become
available. However, whether this annual screening
should continue beyond the age of 70 (ACS does not
mention a fixed upper age limit for the DES-exposed
group) is questionable. As in other familial cancer
screening programmes, the benefits and costs (physical,
psychological and economic) of increased surveillance
in women with a family history of cervical cancer would
need to be established and this surveillance should
therefore be monitored in a research setting. 
When  in  the  future  genetic  predisposition  to
cervical cancer can be identified at a molecular level,
presymptomatic genetic testing will become an option.
The identification of such predisposition might stimulate
compliance to screening programmes, or, in regions
without population screening, it might make cervical
cancer screening available to the women involved.
Moreover, when genetic susceptibility indeed turns out
to act through a decreased host response to HPV
infection, then women with this particular susceptibility
might  be  good  candidates  for  prophylactic  HPV
vaccination [39]. 
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